AustraliaHealth

Healthscope's lenders are poised to endorse a rescue plan that will transform the nation's second-largest private hospital operator into a not-for-profit entity.

Epsilon Healthcare (ASX:EPN) partnered with Puro New Zealand in a multi-year deal to manufacture organic medicinal cannabis.

Neuren Pharmaceuticals (ASX:NEU) secures FDA feedback for NNZ-2591, validating its HIE study path and Pitt Hopkins trial endpoints for a 2026 launch.

Island Pharmaceuticals (ASX:ILA) secured $9 million in strategic funding, raised through a placement of approximately 25.7 million new ordinary shares priced at $0.35 each.

Biome Australia (ASX:BIO) has cleared the final regulatory hurdle to begin a landmark human clinical trial for its proprietary probiotic strain, Lactobacillus plantarum BMB18.

Medical technology innovator OncoSil Medical (ASX:OSL) announced a comprehensive $8 million capital raising initiative.

Ryman Healthcare (ASX:RYM), the trans-Tasman leader in retirement living, announced a sweeping strategic overhaul and a new capital management framework aimed at unlocking value from its $12 billion portfolio.

Telix Pharmaceuticals (ASX:TLX) announced the immediate resignation of board Chair and Non-Executive Director Tiffany Olson.

Rhythm Biosciences (ASX:RHY) has reached a pivotal commercial milestone by executing a multi-year supply agreement with US-based Quansys Biosciences.

Neuren Pharmaceuticals (ASX:NEU) shares plummeted as much as 22% on Feb. 3 morning, following a major regulatory hurdle for its flagship Rett syndrome treatment, trofinetide.

Clinical-stage biopharmaceutical firm Neurotech International (ASX:NTI) has reached a transformative regulatory milestone, receiving Human Research Ethics Committee approval to commence its Beyond Harmony Phase 3 clinical study.

Microbiome health specialist Biome Australia (ASX:BIO) has bolstered its North American presence by entering into a distribution partnership with Fullscript.